Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

• Published in: Haematologica (Roma) 2018-12, Vol.103 (12), p.2079-2087
• Main Authors: Spencer, Andrew, Lentzsch, Suzanne, Weisel, Katja, Avet-Loiseau, Hervé, Mark, Tomer M, Spicka, Ivan, Masszi, Tamas, Lauri, Birgitta, Levin, Mark-David, Bosi, Alberto, Hungria, Vania, Cavo, Michele, Lee, Je-Jung, Nooka, Ajay K, Quach, Hang, Lee, Cindy, Barreto, Wolney, Corradini, Paolo, Min, Chang-Ki, Scott, Emma C, Chanan-Khan, Asher A, Horvath, Noemi, Capra, Marcelo, Beksac, Meral, Ovilla, Roberto, Jo, Jae-Cheol, Shin, Ho-Jin, Sonneveld, Pieter, Soong, David, Casneuf, Tineke, Chiu, Christopher, Amin, Himal, Qi, Ming, Thiyagarajah, Piruntha, Sasser, A Kate, Schecter, Jordan M, Mateos, Maria-Victoria
• Format: Article
• Language: English
• ISSN: 0390-6078; 1592-8721
• DOI: 10.3324/haematol.2018.194118

Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow-up is presented. After 19.4 (range: 0 to 27.7) months of median follow-up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P 2.5-fold higher with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dexamethasone remained consistent with longer follow-up. Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse. clinicaltrials.gov identifier: NCT02136134.